## **Recombinant Human TRAIL Protein**

## Catalog Number: PKSH033422

Note: Centrifuge before opening to ensure complete recovery of vial contents.

| Description    |  |  |  |
|----------------|--|--|--|
| Species        | Human  |  |  |
| Source         | E.coli-derived Human TRAIL protein Arg115-Gly281, with an C-terminal His                 |  |  |
| Calculated MW  | 20.3 kDa   |  |  |
| Observed MW    | 18 kDa   |  |  |
| Accession      | P50591   |  |  |
| Bio-activity   | Measure by its ability to induce cytotoxicity in L929 cells in the presence of           |  |  |
|                | actinomycin D. The $ED_{50}$ for this effect is 10.4-15.4 ng/mL.                         |  |  |
| Properties     |  |  |  |
| Purity         | > 98 % as determined by reducing SDS-PAGE.   |  |  |
| Endotoxin      | < 0.1 EU per µg of the protein as determined by the LAL method.                          |  |  |
| Storage        | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 |  |  |
|                | °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of      |  |  |
|                | reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.                      |  |  |
| Shipping       | This product is provided as lyophilized powder which is shipped with ice packs.          |  |  |
| Formulation    | Lyophilized from sterile PBS,pH 8.0.   |  |  |
|                | Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants         |  |  |
|                | before lyophilization.   |  |  |
|                | Please refer to the specific buffer information in the printed manual.                   |  |  |
| Reconstitution | Please refer to the printed manual for detailed information.                             |  |  |
| Data           |  |  |  |
| kDa            | MK R   |  |  |

| kDa      | MK | R |
|----------|----|---|
| 120      |    |   |
| 90<br>60 | -  |   |
| 40       | -  |   |
| 30       | -  |   |
| 20       | -  |   |
|          | •  | - |
| 14       | -  | - |

> 98 % as determined by reducing SDS-PAGE.

## Background

Human TNFSF10 is a type II transmembrane protein with an intracellular N-terminus and a 'TNF homology domain' ( THD) at the extracellular C terminus. TNFSF10 can interact with several distinct receptors. Two of these receptors that belongs to TNFR superfamily, DR4 (TRAIL-R1) and DR5 (TRAIL-R2/TRICK2), are plasma membrane proteins containing intracellular death domains essential for activating apoptosis. TNFSF10 is promising for cancer therapy because it is cytotoxic and activates apoptosis in the majority of malignant cells, but not in normal cells.

Web:www.elabscience.com